UBS cuts rating on Regeneron stock amid Eylea uncertainty
UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 from $1130.
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’
We recently compiled a list of the Jim Cramer Discusses Joe Rogan, Elon Musk, And These 13 Stocks. In this article, we are ...
Regeneron Pharmaceuticals, Inc. Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the REGN Class Action
SAN DIEGO, CA / ACCESSWIRE / January 15, 2025 / Robbins LLP reminds investors that a class action was filed on behalf of all ...
Claro Advisors LLC Cuts Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Claro Advisors LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 15.7% in the 4th ...
Nasdaq3d
Regeneron To Invest $119.5 Mln In Truveta's Financing Round, Launch Truveta Genome Project
In the pre-market hours, Regeneron's stock is trading at $695, down 0.27 percent on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not ...
Nasdaq3d
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose ...
Nasdaq3d
Regeneron and Truveta Announce Strategic Collaboration for the Truveta Genome Project, Aiming to Expand Genetic Database and Accelerate Drug Discovery
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...
Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – REGN
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want ...
Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Should Contact the Shareholders Foundation in Connection With Lawsuit
NDAQ:REGN) Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Should Contact the Shareholders ...
Regeneron Pharmaceuticals, Inc. (REGN) Securities Fraud: Contact Berger Montague To Discuss Your Rights
On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...
Nasdaq3d
Regeneron Pharma Reports Positive Results From C-POST Trial With Libtayo - Quick Facts
(RTTNews) - Regeneron Pharmaceuticals ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...